⌕
Aptargroup · ATR · NYSE
Tenet 44 · Weak
Compare
$140.33−1.98%At closeTenet 44 · Weak
$140.33−2.84 (−1.98%)
At close: Nov 17, 2026, 4:00 PM ET· NYSE · USD

Aptargroup (ATR) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● GlobeNewsWireNov 16, 2026 · 05:30 ET
Rakovina Therapeutics to Present ATR Inhibitor Data in PTEN-Deficient Prostate Cancer at the 38th EORTC-NCI-AACR Symposium

Second poster of the month for the kt-5000AI program, following the 31st Society for Neuro-Oncology Annual Meeting Second poster of the month for the kt-5000AI program, following the 31st Society for Neuro-Oncology Annua…

● PRNewsWireNov 12, 2026 · 16:10 ETEARNINGS EXPECTED BY FEB 11
Atrium Therapeutics Reports Third Quarter 2026 Financial Results

-- First patient dosed with ATR 1072 in the Corventis™ Phase 1/2 clinical trial in PRKAG2 syndrome -- -- Nonclinical data showed ATR 1072 reversed cardiac glycogen accumulation and improved features of PRKAG2 syndrome --…

● PRNewsWireNov 10, 2026 · 11:34 ET
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of AptarGroup, Inc. (NYSE: ATR)

NEW YORK, Nov. 10, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating AptarGroup, Inc. (NYSE: ATR) on behalf of the company's shareholders. The investigation seeks to determine whether AptarG…

● GlobeNewsWireNov 5, 2026 · 05:30 ET
Rakovina Therapeutics to Present Brain-Penetrant ATR Inhibitor Data at the 31st Society for Neuro-Oncology Annual Meeting

Poster to highlight AI-designed kt-5000AI compounds developed for PTEN-deficient brain tumours Poster to highlight AI-designed kt-5000AI compounds developed for PTEN-deficient brain tumours…

● Zacks Investment ResearchNov 2, 2026 · 10:16 ET
Investing in AptarGroup (ATR)? Don't Miss Assessing Its International Revenue Trends

Examine AptarGroup's (ATR) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.…

● PRNewsWireNov 2, 2026 · 06:30 ET
Atrium Therapeutics to Present Nonclinical Data Showing ATR 1072 Reversed and Improved Features of PRKAG2 Syndrome During HCMS at AHA Scientific Sessions 2026

-- ATR 1072 impacted key characteristics of PRKAG2 syndrome, including accumulation ofcardiac glycogen and cardiac hypertrophy -- -- Data further reinforce scientific rationale for ATR 1072 targeting the root cause ofPRK…

● Seeking AlphaOct 30, 2026 · 17:08 ETEARNINGS EXPECTED BY FEB 11
AptarGroup, Inc. (ATR) Q3 2026 Earnings Call Transcript

AptarGroup, Inc. ( ATR ) Q3 2026 Earnings Call October 30, 2026 9:00 AM EDT Company Participants Marry Skafidas - Senior Vice President of Investor Relations & Communications Gael Touya - CEO, President & Director Vaness…

● MarketBeatOct 30, 2026 · 12:16 ETEARNINGS EXPECTED BY FEB 11
What AptarGroup (ATR) Said on Its Q3 Earnings Call

AptarGroup NYSE: ATR reported third-quarter 2026 sales growth across its three business segments, while adjusted profitability declined from the prior year as emergency medicine destocking and lower margins in Beauty and…

● Zacks Investment ResearchOct 29, 2026 · 20:06 ETEARNINGS EXPECTED BY FEB 11
AptarGroup (ATR) Q3 Earnings and Revenues Beat Estimates

AptarGroup (ATR) came out with quarterly earnings of $1.52 per share, beating the Zacks Consensus Estimate of $1.46 per share. This compares to earnings of $1.62 per share a year ago.…

● GlobeNewsWireOct 28, 2026 · 05:30 ET
Rakovina Therapeutics and Celvion Therapeutics Complete AI Analysis Identifying Priority Cancer Indications for Brain-Penetrant ATR Inhibitor Program

EMphora™ platform integrates clinical evidence and predictive modelling to help identify promising cancer patient populations and guide the next phase of research EMphora™ platform integrates clinical evidence and predic…

● Defense WorldOct 20, 2026 · 03:53 ETEARNINGS EXPECTED BY FEB 11
AptarGroup, Inc. $ATR Stock Bought by State of Alaska Department of Revenue

State of Alaska Department of Revenue raised its holdings in AptarGroup, Inc. (NYSE: ATR) by 53.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm o…

● Defense WorldOct 18, 2026 · 02:15 ET
AptarGroup, Inc. (ATR) – What Are Brokerages Saying About This Stock?

Shares of AptarGroup, Inc. (NYSE: ATR - Get Free Report) have been given a consensus rating of "Moderate Buy" by the ten ratings firms that are currently covering the firm, MarketBeat.com reports. Four research analysts …

● Zacks Investment ResearchOct 5, 2026 · 10:35 ETEARNINGS EXPECTED BY FEB 11
AptarGroup (ATR) Loses 5.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

AptarGroup (ATR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a tre…

● Zacks Investment ResearchSep 25, 2026 · 13:31 ET
3 Packaging Stocks Worth Watching Despite Industry Pressure

Although weak demand and tariffs cloud the Zacks Containers - Paper and Packaging industry's near-term outlook, AVY, ATR and KRT are navigating the challenges well.…

● Defense WorldSep 17, 2026 · 04:17 ETEARNINGS EXPECTED BY FEB 11
AptarGroup, Inc. $ATR Shares Sold by Tidal Investments LLC

Tidal Investments LLC lowered its position in AptarGroup, Inc. (NYSE: ATR) by 24.4% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 17,987 s…

● Defense WorldSep 16, 2026 · 04:17 ETEARNINGS EXPECTED BY FEB 11
VIRGINIA RETIREMENT SYSTEMS ET Al Buys New Holdings in AptarGroup, Inc. $ATR

VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in AptarGroup, Inc. (NYSE: ATR) in a recent quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 4,200 shar…

● Seeking AlphaSep 15, 2026 · 14:31 ET
AptarGroup, Inc. (ATR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

AptarGroup, Inc. (ATR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript…

● Seeking AlphaSep 9, 2026 · 17:17 ET
AptarGroup, Inc. (ATR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

AptarGroup, Inc. (ATR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript…

● PRNewsWireSep 2, 2026 · 07:28 ET
CytoSorbents Announces New Real-World Data Demonstrating Significant Reduction in Severe Bleeding Using CytoSorb in CABG Patients on Ticagrelor and Updates Recent DrugSorb-ATR FDA Pre-Submission Meetings

Patient-level matched analysis of real-world data demonstrated a significant 37% relative reduction in severe bleeding Significant reductions in 24-hour chest tube drainage and red blood cell transfusions were also seen,…

No recent releases where the company itself is speaking.

Kept in their own lane. A press release is the company talking, not reporting.

Expected by Feb 11. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

Article counts from the last market-wide feed page, across every symbol we track and not just ATR · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.